Karyopharm changes co-primary endpoint for Phase 3 SENTRY trial to Abs-TSS; increases sample size to 350

Karyopharm Therapeutics Inc.

Co-primary endpoint changed from TSS50 to Abs-TSS following FDA alignment; SVR35 remains co-primary.
Phase 1 Selinexor+ruxolitinib data showed 79% SVR35 (n=14) and 18.5-point average Abs-TSS improvement (n=9) at week 24.
Total sample size increased to ~350 patients to improve statistical power; top-line data still expected in 2H 2025.
Safety profile remains consistent with no new signals; change supported by key investigators and MPN Research Foundation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.